AVI’s antiviral program ◄◄ H5N1 Player ►► - 500 Beiträge pro Seite
eröffnet am 21.03.06 17:52:17 von
neuester Beitrag 27.05.06 13:22:01 von
neuester Beitrag 27.05.06 13:22:01 von
Beiträge: 23
ID: 1.048.919
ID: 1.048.919
Aufrufe heute: 0
Gesamt: 2.368
Gesamt: 2.368
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 39 Minuten | 131 | |
| vor 59 Minuten | 86 | |
| gestern 20:10 | 65 | |
| gestern 20:44 | 54 | |
| gestern 23:03 | 49 | |
| gestern 22:23 | 34 | |
| gestern 22:51 | 33 | |
| gestern 22:28 | 32 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.653,00 | +1,44 | 315 | |||
| 2. | 2. | 23,050 | -22,73 | 160 | |||
| 3. | 3. | 177,95 | +4,27 | 71 | |||
| 4. | 4. | 10,460 | +3,72 | 51 | |||
| 5. | 5. | 6,2730 | +1,67 | 40 | |||
| 6. | 6. | 4,2175 | +0,70 | 34 | |||
| 7. | 7. | 3,5150 | +0,43 | 32 | |||
| 8. | 9. | 4,4500 | -0,22 | 31 |
Feedback
Moin Moin,
ich habe hier einen aussichtsreichen Kandidaten in Sachen birdflu gefunden, mich wundert, dass es hier noch keinen Thread dazu gibt, deswegen nun der Faktenthread von mir
AVI’s antiviral program uses NEUGENE antisense compounds to combat disease by targeting single–stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, and Ebola virus. AVI has also evaluated Avicine, a therapeutic cancer vaccine, in six clinical trials involving colorectal and pancreatic cancer; completed Phase Ib/II trials of AVI-4557 targeting drug metabolism; and evaluated Phase I trials of AVI-4126 targeting polycystic kidney disease
In initial experiments, eight NeuGene antisense compounds were developed to target regions of the influenza virus genome believed to be critical to virus survival. AVI also selected regions of the virus that are highly conserved across all six virus subtypes that cause human disease. These candidates have been tested in various viral culture assays with several collaborators, including Professor J. Chen and Quing Ge at the Massachusetts Institute of Technology. Several agents that were both potent and specific for Influenza A have been identified as suppressing replication of H1N1. One agent was found to inhibit both viral transcription and replication. Moreover, combinations of two agents were routinely twofold to threefold more active than single agents alone, and one combination of two agents exhibited sevenfold to eightfold improvement in viral reduction compared with a single agent.
Additional experiments showed that a single mismatch within the targeted region of the virus caused less than a 10 percent loss of activity of the drug. This provides strong evidence that a single NeuGene antisense drug could potentially shut down all the flu virus subtypes, including the H5N1 avian flu, even if a mutation occurred in these highly conserved regions
Ich wünsche mir eine rege Beteiligung
ich habe hier einen aussichtsreichen Kandidaten in Sachen birdflu gefunden, mich wundert, dass es hier noch keinen Thread dazu gibt, deswegen nun der Faktenthread von mir
AVI’s antiviral program uses NEUGENE antisense compounds to combat disease by targeting single–stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, and Ebola virus. AVI has also evaluated Avicine, a therapeutic cancer vaccine, in six clinical trials involving colorectal and pancreatic cancer; completed Phase Ib/II trials of AVI-4557 targeting drug metabolism; and evaluated Phase I trials of AVI-4126 targeting polycystic kidney disease
In initial experiments, eight NeuGene antisense compounds were developed to target regions of the influenza virus genome believed to be critical to virus survival. AVI also selected regions of the virus that are highly conserved across all six virus subtypes that cause human disease. These candidates have been tested in various viral culture assays with several collaborators, including Professor J. Chen and Quing Ge at the Massachusetts Institute of Technology. Several agents that were both potent and specific for Influenza A have been identified as suppressing replication of H1N1. One agent was found to inhibit both viral transcription and replication. Moreover, combinations of two agents were routinely twofold to threefold more active than single agents alone, and one combination of two agents exhibited sevenfold to eightfold improvement in viral reduction compared with a single agent.
Additional experiments showed that a single mismatch within the targeted region of the virus caused less than a 10 percent loss of activity of the drug. This provides strong evidence that a single NeuGene antisense drug could potentially shut down all the flu virus subtypes, including the H5N1 avian flu, even if a mutation occurred in these highly conserved regions
Ich wünsche mir eine rege Beteiligung
Avian influenza – situation in Azerbaijan - update 2
21 March 2006
Samples from 11 patients under investigation in Azerbaijan for possible H5N1 infection have now been tested at a WHO collaborating laboratory in the United Kingdom. Positive H5N1 results were obtained for seven of these patients. Five cases were fatal.
Today is an official holiday in Azerbaijan. The government will issue an official statement on the situation shortly.
Six of the cases occurred in Salyan Rayon in the south-eastern part of the country. All six cases resided in the small Daikyand settlement of around 800 homes.
A 17-year-old girl died on 23 February. Her first cousin, a 20-year-old woman, died on 3 March. The 16-year-old brother of this woman died on 10 March. A 17-year-old girl, a close friend of the family, died on 8 March. All four of these cases lived together or near each other. The source of their infection is presently under investigation.
The additional two cases in Salyan involve a 10-year-old boy, who has recovered, and a 15-year-old girl, who is hospitalized in critical condition.
The seventh case occurred in a 21-year-old woman from the western rayon of Tarter. She died on 9 March.
Two additional patients, from Salyan and the adjacent rayon of Neftchela, have been hospitalized with symptoms of bilateral pneumonia. Testing of these patients is presently under way.
Last week, WHO strengthened its field team in Azerbaijan to include experts in clinical management and infection control and additional senior epidemiologists.
Over the weekend, a field investigation in Salyan, jointly conducted by WHO and the Azeri Ministry of Health, found some evidence that carcasses of numerous swans, dead for some weeks but not buried, may have been collected by residents as a source of feathers. In this community, the defeathering of birds is a task usually undertaken by adolescent girls and young women. The WHO team is today investigating whether this practice may have been the source of infection in Daikyand, where the majority of cases have occurred in females between the ages of 15 and 20 years. Interviews with surviving family members have failed to uncover a history of direct exposure to dead or diseased poultry for several of the cases.
Excellent collaboration between the Ministry of Health and the WHO team continues. WHO is confident that ongoing house-to-house surveillance for cases of influenza-like illness, undertaken by more than 90 local medical teams in Salyan and Tarter, will detect patients requiring further investigation. On-site diagnostic capacity continues to be provided by the US Naval Medical Research Unit 3 (NAMRU-3). A better understanding of the situation in animals is, however, urgently needed.
http://www.who.int/csr/don/2006_03_21a/en/index.html
21 March 2006
Samples from 11 patients under investigation in Azerbaijan for possible H5N1 infection have now been tested at a WHO collaborating laboratory in the United Kingdom. Positive H5N1 results were obtained for seven of these patients. Five cases were fatal.
Today is an official holiday in Azerbaijan. The government will issue an official statement on the situation shortly.
Six of the cases occurred in Salyan Rayon in the south-eastern part of the country. All six cases resided in the small Daikyand settlement of around 800 homes.
A 17-year-old girl died on 23 February. Her first cousin, a 20-year-old woman, died on 3 March. The 16-year-old brother of this woman died on 10 March. A 17-year-old girl, a close friend of the family, died on 8 March. All four of these cases lived together or near each other. The source of their infection is presently under investigation.
The additional two cases in Salyan involve a 10-year-old boy, who has recovered, and a 15-year-old girl, who is hospitalized in critical condition.
The seventh case occurred in a 21-year-old woman from the western rayon of Tarter. She died on 9 March.
Two additional patients, from Salyan and the adjacent rayon of Neftchela, have been hospitalized with symptoms of bilateral pneumonia. Testing of these patients is presently under way.
Last week, WHO strengthened its field team in Azerbaijan to include experts in clinical management and infection control and additional senior epidemiologists.
Over the weekend, a field investigation in Salyan, jointly conducted by WHO and the Azeri Ministry of Health, found some evidence that carcasses of numerous swans, dead for some weeks but not buried, may have been collected by residents as a source of feathers. In this community, the defeathering of birds is a task usually undertaken by adolescent girls and young women. The WHO team is today investigating whether this practice may have been the source of infection in Daikyand, where the majority of cases have occurred in females between the ages of 15 and 20 years. Interviews with surviving family members have failed to uncover a history of direct exposure to dead or diseased poultry for several of the cases.
Excellent collaboration between the Ministry of Health and the WHO team continues. WHO is confident that ongoing house-to-house surveillance for cases of influenza-like illness, undertaken by more than 90 local medical teams in Salyan and Tarter, will detect patients requiring further investigation. On-site diagnostic capacity continues to be provided by the US Naval Medical Research Unit 3 (NAMRU-3). A better understanding of the situation in animals is, however, urgently needed.
http://www.who.int/csr/don/2006_03_21a/en/index.html
Antwort auf Beitrag Nr.: 20.893.325 von [KERN]Codex am 21.03.06 17:58:18hallo kern codex,
bin ebenfalls investiert und würde mich freuen wenn du eine aktuelle, CT momentaufnahme abgeben könntest.
danke, drago.....
bin ebenfalls investiert und würde mich freuen wenn du eine aktuelle, CT momentaufnahme abgeben könntest.
danke, drago.....
Heute geht es ab 
Name
Avi Biopharma
Last Price
7.3500
Net Change
+0.7600
Shares Matched
638,457
Orders Entered
5,658
Last Match Time
9:36:24.191
Market
NM
Previous Close
6.5900
Percent Change
+11.53%
Shares Entered
1,362,055
Open Orders
96
Last Order Time
9:36:25.560
Avi Biopharma
Last Price
7.3500
Net Change
+0.7600
Shares Matched
638,457
Orders Entered
5,658
Last Match Time
9:36:24.191
Market
NM
Previous Close
6.5900
Percent Change
+11.53%
Shares Entered
1,362,055
Open Orders
96
Last Order Time
9:36:25.560
Trading Spotlight
Antwort auf Beitrag Nr.: 21.012.137 von [KERN]Codex am 30.03.06 16:36:38Name
Avi Biopharma
Last Price
7.6300
Net Change
+1.0400
Shares Matched
3,276,199
Orders Entered
64,804
Last Match Time
15:41:36.084
Market
NM
Previous Close
6.5900
Percent Change
+15.78%
Shares Entered
11,686,262
Open Orders
143
Last Order Time
15:41:42.374
STRONG BUY!
Avi Biopharma
Last Price
7.6300
Net Change
+1.0400
Shares Matched
3,276,199
Orders Entered
64,804
Last Match Time
15:41:36.084
Market
NM
Previous Close
6.5900
Percent Change
+15.78%
Shares Entered
11,686,262
Open Orders
143
Last Order Time
15:41:42.374
STRONG BUY!
9:02AM AVI BioPharma reports successful research results of Influenza virus, shows efficacy against Avian (AVII) 6.59 : Co announces presentation of research results titled "Inhibition of Multiple Subtypes of Influenza A Virus in Cell Culture with Morpholino Oligomers". Co's Senior VP of Research comments, AVI. "The key finding here is that our NEUGENE therapeutics continue to show efficacy against all strains of influenza A, including H5N1, the avian influenza strain that is currently causing global concern as a potential pandemic pathogen."
+17%
+17%
AVI BioPharma Up Bird Flu Trial Plan
Thursday March 30, 1:54 pm ET
AVI BioPharma Inc. Shares Rise on Plans to Apply to the FDA for a Flu Drug Trial This Year
PORTLAND, Ore. (AP) -- Shares of AVI BioPharma Inc. jumped Thursday after the biotech company said it plans to file papers with the Food and Drug Administration this year to begin clinical trials of its Neugene line of antisense drugs.
AVI BioPharma rose 79 cents, or 12 percent, to $7.38 in afternoon trading on the Nasdaq at more than double their average volume. Shares have traded between $2.05 and $9.20 over the past 52 weeks.
The company said it will base the application on lab studies showing that Neugene antisense drugs are effective in stopping the replication of influenza viruses, including the bird flu virus strain H5N1. Antisense drugs interfere with genetic processes to stop the manufacture of harmful proteins.
Shares of other biotechnology companies developing products to fight bird flu, such as Hemispherx Biopharma Inc. and Novavax Inc., also rose.
Shares of Hemispherx BioPharma rose 10 cents, or 2.8 percent, to $3.66 on the American Stock Exchange, and Novavax shares grew by 33 cents, or 4.4 percent, to $7.84 on the Nasdaq.
Antwort auf Beitrag Nr.: 21.019.621 von [KERN]Codex am 30.03.06 22:58:00Was bald passieren wird: in 3 Wochen beginnt in Alaska der Frühling, Alaska liegt innerhalb von 2 weltweiten Vogelrouten, die Forscher stehen schon da und warten auf den ersten h5n1 Fall, danach machen wir richtig CASH 
Bird Flu on Its Way: First Stop, Alaska
March 13, 2006 — The approach of spring brings not only the return of wild migratory birds to American shores but also the threat of avian influenza.
And this is the man whose job it is to spot it. Working on the Bering Sea at the tip of Alaska, Paul Flint, a Research Wildlife Biologist with the U.S. Geological Survey, is the point man in America\'s campaign against bird flu.
"We\'re targeting them as soon as we can from when they arrive from Asia to here," says Flint. "We\'re going to be on the ground in front of the bird migration waiting for the birds to arrive."
Along with Izenbek Wildlife Refuge manager Sandra Siekaniec of the U.S. Fish and Wildlife Service, and other federal and state agencies, Flint\'s assignment is to identify the first infected birds carrying the virus from Asia during the spring migration, and to sound the alarm.
"Alaska is one of the forefronts where it is most likely to arrive first because of its unique position as a crossroads of two international flyways: one on the Asian side of things and the other one on the North American side of things," explains Flint.
U.S. spy satellites have tracked the infected flocks, which started migrating from Asia and are now heading north to Siberia and Alaska, where they will soon mingle with flocks from the North American flyways.
"You can\'t build a cage around the United States," says Agriculture Secretary Michael Johanns, of the inevitably of the virus\' arrival in America. "That\'s not possible."
Johanns tells ABC News that a bird flu outbreak in Alaska could come in as little as three weeks. That could mean further outbreaks in the lower 48 states by August.
The spread of the disease by wild migratory birds — traveling from Asia to Africa and Europe — has been much more rapid than first predicted. In four months, the virus has spread from 16 to 37 countries. Scientists now predict Great Britain will be next.
"We are losing our ability to forecast what\'s going on," says Laurie Garrett, the senior fellow for global health at the Council on Foreign Relations.
U.S. officials therefore count heavily on the early-warning system in place in Alaska, where suspect birds, including the Eastern Yellow Wagtail and the Dunlin, will be captured and tested.
Scientists here say, however, that given Alaska\'s remote location, it will take at least a month to confirm any outbreak, which reduces the lead time the rest of the country has to get ready.
While the virus is still not easily transmitted to humans, a report released today by Health and Human Services Secretary Michael Leavitt confirms that H5N1, a mutating type of avian influenza virus, continues to spread and change in unexpected ways. Even though the government had ordered millions of doses of vaccine, the emergence of a second, more lethal strain means another vaccine will now have to be developed.
ABC News\' Maddy Sauer and Rhonda Schwartz contributed to this report.
Bird Flu on Its Way: First Stop, Alaska
March 13, 2006 — The approach of spring brings not only the return of wild migratory birds to American shores but also the threat of avian influenza.
And this is the man whose job it is to spot it. Working on the Bering Sea at the tip of Alaska, Paul Flint, a Research Wildlife Biologist with the U.S. Geological Survey, is the point man in America\'s campaign against bird flu.
"We\'re targeting them as soon as we can from when they arrive from Asia to here," says Flint. "We\'re going to be on the ground in front of the bird migration waiting for the birds to arrive."
Along with Izenbek Wildlife Refuge manager Sandra Siekaniec of the U.S. Fish and Wildlife Service, and other federal and state agencies, Flint\'s assignment is to identify the first infected birds carrying the virus from Asia during the spring migration, and to sound the alarm.
"Alaska is one of the forefronts where it is most likely to arrive first because of its unique position as a crossroads of two international flyways: one on the Asian side of things and the other one on the North American side of things," explains Flint.
U.S. spy satellites have tracked the infected flocks, which started migrating from Asia and are now heading north to Siberia and Alaska, where they will soon mingle with flocks from the North American flyways.
"You can\'t build a cage around the United States," says Agriculture Secretary Michael Johanns, of the inevitably of the virus\' arrival in America. "That\'s not possible."
Johanns tells ABC News that a bird flu outbreak in Alaska could come in as little as three weeks. That could mean further outbreaks in the lower 48 states by August.
The spread of the disease by wild migratory birds — traveling from Asia to Africa and Europe — has been much more rapid than first predicted. In four months, the virus has spread from 16 to 37 countries. Scientists now predict Great Britain will be next.
"We are losing our ability to forecast what\'s going on," says Laurie Garrett, the senior fellow for global health at the Council on Foreign Relations.
U.S. officials therefore count heavily on the early-warning system in place in Alaska, where suspect birds, including the Eastern Yellow Wagtail and the Dunlin, will be captured and tested.
Scientists here say, however, that given Alaska\'s remote location, it will take at least a month to confirm any outbreak, which reduces the lead time the rest of the country has to get ready.
While the virus is still not easily transmitted to humans, a report released today by Health and Human Services Secretary Michael Leavitt confirms that H5N1, a mutating type of avian influenza virus, continues to spread and change in unexpected ways. Even though the government had ordered millions of doses of vaccine, the emergence of a second, more lethal strain means another vaccine will now have to be developed.
ABC News\' Maddy Sauer and Rhonda Schwartz contributed to this report.
Das sind die Werte die ich habe
Bei 2€uro wäre mir der Einstieg leichter gefallen 
Umsätze in D sehr bescheiden, dafür in USA enorm
Watch out ...
Umsätze in D sehr bescheiden, dafür in USA enorm
Watch out ...
Antwort auf Beitrag Nr.: 21.019.826 von TimeFactor am 30.03.06 23:07:35Wall Street News Alert: Hot Stock Alert Issued on HBSC! March 31, 2006
http://www.pcquote.com/stocks/readNews.php?symbol=AVII&id=29…
von heute
http://www.pcquote.com/stocks/readNews.php?symbol=AVII&id=29…
von heute
Global Demand Supports Development of Avian Flu Treatments and Antiviral Drugs
Monday April 3, 9:00 am ET
Biotech and Healthcare Companies Present Potential Solutions to the Bird Flu
POINT ROBERTS, WA and DELTA, BC--(MARKET WIRE)--Apr 3, 2006 -- www.China-AsiaStocks.com (CAS) and www.BiotechIndustryStocks.com (BIS) , investor and industry news portals for the China-Asia and biotechnology sectors, feature "Global Demand Boosts Avian Flu Vaccine Market," for investors and industry following developments in the vaccine market. Biotech and Healthcare companies: Bridgetech Holdings International Inc., Generex Biotech, AVI Biopharma Inc., Hemispherx Biopharma, Inc, Carrington Laboratories and Aethlon Medical discuss unique approaches to this potential global dilemma and offer insight to possible solutions.
Dr. Carlton Turner, President and CEO of Carrington Laboratories, gave an overview on the market, commenting that, "Policymakers from around the world are responding as best they can to the threat of an H5 Avian Flu pandemic. The challenge lies in trying to find the right antigen, producing enough of it to protect the world\'s population and then finding a way to deliver it to large populations efficiently."
Michael Chermak, CEO for Bridgetech Holdings International Inc (Other OTC:BGTH.PK - News), has provided insights with respect to the effect the Avian Flu has had on China\'s healthcare market, "The impact of the Avian Flu outbreak on the Chinese healthcare system has been profound. The resulting self examination has created a sense of urgency, regarding the modernization and improvement of the entire system."
Vice President of Generex (NasdaqSC:GNBT - News) and President of Antigen Express, Dr. Eric Vonhofe, expressed great confidence in their product, explaining that," Last fall, the government paid about $100 million for an egg-based vaccine, but that will probably be enough for only about 3 million people. In contrast, our vaccine which is synthetic can be made on a 100 kg scale quickly, efficiently and at a relatively inexpensive rate."
AVI Biopharma Inc., a producer of antiviral drugs, has established avian influenza H5N1 as a priority within the company. Michael Hubbard, Director of Investor Relations for the company, said that, "We are moving as quickly as we can on Avian Flu, given the urgency. As soon as we have the safety data, we can apply for a new drug application with the FDA, which we hope to do before year\'s end." Dr. David Strayer, Medical Director at Hemispherx Biopharma, Inc. (AMEX:HEB - News), also pointed out that, "This area could move very rapidly because there is an urgent need for a better way to treat and prevent Avian influenza. I think there is great potential here for our company."
However, antiviral drugs currently being stockpiled as part of a global strategy to treat Avian Flu may have little therapeutic value once the deadly cytokine store has been triggered. As explained by James A. Joyce, Chairman and CEO at Aethlon Medican Inc. (OTC BB:AEMD.OB - News), "Once a cytokine storm has been triggered, the Hemopurifier could serve as the first, and perhaps only option for treating H5N1 infected patients."
To Read "Global Demand Boosts Avian Flu Vaccine Market" In Full Click Here: http://www.China-AsiaStocks.com/Articles/Avian_Flu.asp
About our CAS and BIS Portals:
www.China-AsiaStocks.com and www.BiotechIndustryStocks.com portals within the InvestorIdeas.com content umbrella, offer investors research, news and links to public companies within the China-Asia and Biotechnology sectors. CAS and BIS do not make recommendations, but offer unique free information portals to research news, articles, interviews and a growing list of participating public companies in the China-Asia and biotech industry.
China-AsiaStocks.com includes a comprehensive and growing list of China Asia Stocks: http://www.China-AsiaStocks.com/Companies/China-AsiaStocks/S…
To visit our China-Asia portal in Chinese click here: http://www.china-asiastocks.com/CAS/
Featured Sponsor Participating in the China Asia Market: (CAS is compensated by Bridgetech Holding International as disclosed in disclaimer.)
Bridgetech Holdings International Inc (Other OTC:BGTH.PK - News) a leading distributor of western-based healthcare products and medical technology in China. For more info: http://www.china-asiastocks.com/CO/BGTH/Default.asp or visit the company\'s website at www.bthi.com.
Investorideas.com Disclaimer: www.InvestorIdeas.com/About/Disclaimer.asp Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by its "featured companies." Bridgetech Holdings International, Inc five thousand dollars per month and ten thousand shares of 144 stock as a one time fee .Additionally , Aethlon Medical was a former featured company on Investorideas.com, please review previous clients disclaimer.
Contact:
For More Information Contact:
Dawn Van Zant
800-665-0411
Email: Email Contact
Fei Wang
866-948-0848
Email: Email Contact
Web Site: http://www.InvestorIdeas.com
Monday April 3, 9:00 am ET
Biotech and Healthcare Companies Present Potential Solutions to the Bird Flu
POINT ROBERTS, WA and DELTA, BC--(MARKET WIRE)--Apr 3, 2006 -- www.China-AsiaStocks.com (CAS) and www.BiotechIndustryStocks.com (BIS) , investor and industry news portals for the China-Asia and biotechnology sectors, feature "Global Demand Boosts Avian Flu Vaccine Market," for investors and industry following developments in the vaccine market. Biotech and Healthcare companies: Bridgetech Holdings International Inc., Generex Biotech, AVI Biopharma Inc., Hemispherx Biopharma, Inc, Carrington Laboratories and Aethlon Medical discuss unique approaches to this potential global dilemma and offer insight to possible solutions.
Dr. Carlton Turner, President and CEO of Carrington Laboratories, gave an overview on the market, commenting that, "Policymakers from around the world are responding as best they can to the threat of an H5 Avian Flu pandemic. The challenge lies in trying to find the right antigen, producing enough of it to protect the world\'s population and then finding a way to deliver it to large populations efficiently."
Michael Chermak, CEO for Bridgetech Holdings International Inc (Other OTC:BGTH.PK - News), has provided insights with respect to the effect the Avian Flu has had on China\'s healthcare market, "The impact of the Avian Flu outbreak on the Chinese healthcare system has been profound. The resulting self examination has created a sense of urgency, regarding the modernization and improvement of the entire system."
Vice President of Generex (NasdaqSC:GNBT - News) and President of Antigen Express, Dr. Eric Vonhofe, expressed great confidence in their product, explaining that," Last fall, the government paid about $100 million for an egg-based vaccine, but that will probably be enough for only about 3 million people. In contrast, our vaccine which is synthetic can be made on a 100 kg scale quickly, efficiently and at a relatively inexpensive rate."
AVI Biopharma Inc., a producer of antiviral drugs, has established avian influenza H5N1 as a priority within the company. Michael Hubbard, Director of Investor Relations for the company, said that, "We are moving as quickly as we can on Avian Flu, given the urgency. As soon as we have the safety data, we can apply for a new drug application with the FDA, which we hope to do before year\'s end." Dr. David Strayer, Medical Director at Hemispherx Biopharma, Inc. (AMEX:HEB - News), also pointed out that, "This area could move very rapidly because there is an urgent need for a better way to treat and prevent Avian influenza. I think there is great potential here for our company."
However, antiviral drugs currently being stockpiled as part of a global strategy to treat Avian Flu may have little therapeutic value once the deadly cytokine store has been triggered. As explained by James A. Joyce, Chairman and CEO at Aethlon Medican Inc. (OTC BB:AEMD.OB - News), "Once a cytokine storm has been triggered, the Hemopurifier could serve as the first, and perhaps only option for treating H5N1 infected patients."
To Read "Global Demand Boosts Avian Flu Vaccine Market" In Full Click Here: http://www.China-AsiaStocks.com/Articles/Avian_Flu.asp
About our CAS and BIS Portals:
www.China-AsiaStocks.com and www.BiotechIndustryStocks.com portals within the InvestorIdeas.com content umbrella, offer investors research, news and links to public companies within the China-Asia and Biotechnology sectors. CAS and BIS do not make recommendations, but offer unique free information portals to research news, articles, interviews and a growing list of participating public companies in the China-Asia and biotech industry.
China-AsiaStocks.com includes a comprehensive and growing list of China Asia Stocks: http://www.China-AsiaStocks.com/Companies/China-AsiaStocks/S…
To visit our China-Asia portal in Chinese click here: http://www.china-asiastocks.com/CAS/
Featured Sponsor Participating in the China Asia Market: (CAS is compensated by Bridgetech Holding International as disclosed in disclaimer.)
Bridgetech Holdings International Inc (Other OTC:BGTH.PK - News) a leading distributor of western-based healthcare products and medical technology in China. For more info: http://www.china-asiastocks.com/CO/BGTH/Default.asp or visit the company\'s website at www.bthi.com.
Investorideas.com Disclaimer: www.InvestorIdeas.com/About/Disclaimer.asp Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by its "featured companies." Bridgetech Holdings International, Inc five thousand dollars per month and ten thousand shares of 144 stock as a one time fee .Additionally , Aethlon Medical was a former featured company on Investorideas.com, please review previous clients disclaimer.
Contact:
For More Information Contact:
Dawn Van Zant
800-665-0411
Email: Email Contact
Fei Wang
866-948-0848
Email: Email Contact
Web Site: http://www.InvestorIdeas.com
AVI BioPharma Up Bird Flu Trial Plan
Thursday March 30, 1:54 pm ET
AVI BioPharma Inc. Shares Rise on Plans to Apply to the FDA for a Flu Drug Trial This Year
PORTLAND, Ore. (AP) -- Shares of AVI BioPharma Inc. jumped Thursday after the biotech company said it plans to file papers with the Food and Drug Administration this year to begin clinical trials of its Neugene line of antisense drugs.
ADVERTISEMENT
AVI BioPharma rose 79 cents, or 12 percent, to $7.38 in afternoon trading on the Nasdaq at more than double their average volume. Shares have traded between $2.05 and $9.20 over the past 52 weeks.
The company said it will base the application on lab studies showing that Neugene antisense drugs are effective in stopping the replication of influenza viruses, including the bird flu virus strain H5N1. Antisense drugs interfere with genetic processes to stop the manufacture of harmful proteins.
Shares of other biotechnology companies developing products to fight bird flu, such as Hemispherx Biopharma Inc. and Novavax Inc., also rose.
Shares of Hemispherx BioPharma rose 10 cents, or 2.8 percent, to $3.66 on the American Stock Exchange, and Novavax shares grew by 33 cents, or 4.4 percent, to $7.84 on the Nasdaq.
Thursday March 30, 1:54 pm ET
AVI BioPharma Inc. Shares Rise on Plans to Apply to the FDA for a Flu Drug Trial This Year
PORTLAND, Ore. (AP) -- Shares of AVI BioPharma Inc. jumped Thursday after the biotech company said it plans to file papers with the Food and Drug Administration this year to begin clinical trials of its Neugene line of antisense drugs.
ADVERTISEMENT
AVI BioPharma rose 79 cents, or 12 percent, to $7.38 in afternoon trading on the Nasdaq at more than double their average volume. Shares have traded between $2.05 and $9.20 over the past 52 weeks.
The company said it will base the application on lab studies showing that Neugene antisense drugs are effective in stopping the replication of influenza viruses, including the bird flu virus strain H5N1. Antisense drugs interfere with genetic processes to stop the manufacture of harmful proteins.
Shares of other biotechnology companies developing products to fight bird flu, such as Hemispherx Biopharma Inc. and Novavax Inc., also rose.
Shares of Hemispherx BioPharma rose 10 cents, or 2.8 percent, to $3.66 on the American Stock Exchange, and Novavax shares grew by 33 cents, or 4.4 percent, to $7.84 on the Nasdaq.
AVI BioPharma Provides Update on Hepatitis C Virus Clinical Trial Status
Thursday April 20, 9:00 am ET
Data from the Phase I/II Accepted for Oral Platform Presentation at ICAR
PORTLAND, Ore.--(BUSINESS WIRE)--April 20, 2006--AVI BioPharma, Inc. (Nasdaq:AVII - News), today issued an update on the status of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection. The trial is designed to assess the safety, tolerability, pharmacokinetics (PK) and viral response to treatment with AVI's proprietary NEUGENE® antisense compound AVI-4065 among healthy volunteers and patients with HCV.
The first phase of this study was reported preliminarily in January 2006 and completed in March 2006. The trial evaluated 31 healthy volunteers who received 14 consecutive days of treatment of AVI-4065 at three dosage levels. Data from the second phase of the study, assessing HCV virological responses in patients with chronic active HCV, was anticipated by early April. Unexpected delays in final qualification of some clinical sites have delayed release of preliminary data. The study is actively enrolling HCV patients at four clinical sites. While some patients have completed the study through day 45, more patients must reach day 28 before meaningful virological response data can be collected.
AVI expects to present data from the second phase of the clinical trial at the International Conference on Antiviral Research (ICAR) annual meeting on May 10. AVI's presentation at ICAR, "AVI-4065, an Antisense Approach to Active HCV Infection: Preclinical and Clinical Evaluation," has been selected for an oral platform presentation. More details are available at http://www.georgetown.edu/research/arc/ISAR.
In the second phase of this clinical trial, patients with HCV are stratified into two cohorts, one composed of patients who have not received previous treatment and the other composed of patients who have failed conventional interferon and ribavirin treatment. In addition to efficacy as measured by HCV virological responses to treatment with AVI-4065, the study will continue to assess the safety, tolerability and pharmacokinetics. Patients will also be monitored for four months following treatment to assess the duration of the HCV virological response to AVI-4065.
"We look forward to presenting data from the second phase of our HCV trial as a platform presentation at ICAR," said Denis R. Burger, Ph.D., chief executive officer of AVI. "Although it is disappointing that a slow start to the study prevents release of preliminary data today, the trial is on track. Thus far, there have been no safety or tolerability issues in either cohort of patients receiving AVI-4065."
Dr. Mark Holodniy, M.D., F.A.C.P., professor of medicine at Stanford University School of Medicine and director of the Department of Veterans Affairs Public Health Research & Consultation Program located at the Veterans Affairs Palo Alto Health Care System in Palo Alto, Calif., is the principal investigator for the trial.
HCV is a single-stranded RNA virus. Because HCV and other single-stranded RNA viruses have relatively simple genetic structures, they are attractive targets for AVI's NEUGENE antisense, which is designed to target conserved portions of the viral genetic code that are not likely to mutate over time.
About Hepatitis C Infection
Chronic HCV infection causes an inflammation of the liver that can result in the development of cirrhosis, liver cancer or liver failure. According to the World Health Organization, approximately 170 million people worldwide are chronically infected with HCV. It is the most common chronic blood-borne infection in the developed world and the leading cause of liver transplants in the U.S. The Centers for Disease Control and Prevention estimates that approximately 3.9 million Americans have been infected with HCV, of whom 2.7 million are chronically infected.
The Hepatitis Foundation International estimates that between 8,000 and 10,000 people die annually in the U.S. from HCV-related cirrhosis or liver cancer. The current treatment for HCV, 24 to 48 weeks of therapy with pegylated interferon alpha and ribavirin, is successful in less than half the patients infected with HCV genotype 1, the most common form of the virus in the U.S. Furthermore, this treatment has numerous side effects, some of them severe, which make it difficult for nearly half of initially treated patients to tolerate the recommended dosages and duration of treatment.
About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI has introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. More information about AVI is available on the company's Web site at http://www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
Thursday April 20, 9:00 am ET
Data from the Phase I/II Accepted for Oral Platform Presentation at ICAR
PORTLAND, Ore.--(BUSINESS WIRE)--April 20, 2006--AVI BioPharma, Inc. (Nasdaq:AVII - News), today issued an update on the status of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection. The trial is designed to assess the safety, tolerability, pharmacokinetics (PK) and viral response to treatment with AVI's proprietary NEUGENE® antisense compound AVI-4065 among healthy volunteers and patients with HCV.
The first phase of this study was reported preliminarily in January 2006 and completed in March 2006. The trial evaluated 31 healthy volunteers who received 14 consecutive days of treatment of AVI-4065 at three dosage levels. Data from the second phase of the study, assessing HCV virological responses in patients with chronic active HCV, was anticipated by early April. Unexpected delays in final qualification of some clinical sites have delayed release of preliminary data. The study is actively enrolling HCV patients at four clinical sites. While some patients have completed the study through day 45, more patients must reach day 28 before meaningful virological response data can be collected.
AVI expects to present data from the second phase of the clinical trial at the International Conference on Antiviral Research (ICAR) annual meeting on May 10. AVI's presentation at ICAR, "AVI-4065, an Antisense Approach to Active HCV Infection: Preclinical and Clinical Evaluation," has been selected for an oral platform presentation. More details are available at http://www.georgetown.edu/research/arc/ISAR.
In the second phase of this clinical trial, patients with HCV are stratified into two cohorts, one composed of patients who have not received previous treatment and the other composed of patients who have failed conventional interferon and ribavirin treatment. In addition to efficacy as measured by HCV virological responses to treatment with AVI-4065, the study will continue to assess the safety, tolerability and pharmacokinetics. Patients will also be monitored for four months following treatment to assess the duration of the HCV virological response to AVI-4065.
"We look forward to presenting data from the second phase of our HCV trial as a platform presentation at ICAR," said Denis R. Burger, Ph.D., chief executive officer of AVI. "Although it is disappointing that a slow start to the study prevents release of preliminary data today, the trial is on track. Thus far, there have been no safety or tolerability issues in either cohort of patients receiving AVI-4065."
Dr. Mark Holodniy, M.D., F.A.C.P., professor of medicine at Stanford University School of Medicine and director of the Department of Veterans Affairs Public Health Research & Consultation Program located at the Veterans Affairs Palo Alto Health Care System in Palo Alto, Calif., is the principal investigator for the trial.
HCV is a single-stranded RNA virus. Because HCV and other single-stranded RNA viruses have relatively simple genetic structures, they are attractive targets for AVI's NEUGENE antisense, which is designed to target conserved portions of the viral genetic code that are not likely to mutate over time.
About Hepatitis C Infection
Chronic HCV infection causes an inflammation of the liver that can result in the development of cirrhosis, liver cancer or liver failure. According to the World Health Organization, approximately 170 million people worldwide are chronically infected with HCV. It is the most common chronic blood-borne infection in the developed world and the leading cause of liver transplants in the U.S. The Centers for Disease Control and Prevention estimates that approximately 3.9 million Americans have been infected with HCV, of whom 2.7 million are chronically infected.
The Hepatitis Foundation International estimates that between 8,000 and 10,000 people die annually in the U.S. from HCV-related cirrhosis or liver cancer. The current treatment for HCV, 24 to 48 weeks of therapy with pegylated interferon alpha and ribavirin, is successful in less than half the patients infected with HCV genotype 1, the most common form of the virus in the U.S. Furthermore, this treatment has numerous side effects, some of them severe, which make it difficult for nearly half of initially treated patients to tolerate the recommended dosages and duration of treatment.
About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI has introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. More information about AVI is available on the company's Web site at http://www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
nachbörslich 6,85 USD
was geht den hier heute ab?
.....gute frage !?! weiss jemand mehr ????
Da ich schon am 20. Januar aus der Aktie raus bin (siehe Ebola Thread) verfolge ich die Aktie nur noch am Rande - hat sich ja auch bis heute nicht viel getan.
Offenbar waren die Zwischenresultate einer Wirksamkeits-Studie beim Menschen ziemlich lau und konnten auch durch schöne Rhetorik nicht gebessert werden. Man muss offenbar andere Dosierungsschemate probieren (wird als option verkauft ...)
Lest mal den folgenden Artikel:
(meine Vermutung, dass die ein gutes Stück auf der Vogelgrippewelle
mitgepusht haben, hat sich damit wohl bestätigt ...)
http://biz.yahoo.com/bw/060510/20060510005293.html?.v=1
Press Release Source: AVI BioPharma, Inc.
AVI BioPharma Presents Initial Results on Hepatitis C Virus Clinical Trial at the International Conference on Antiviral Research Annual Meeting
Wednesday May 10, 9:00 am ET
PORTLAND, Ore.--(BUSINESS WIRE)--May 10, 2006--AVI BioPharma, Inc. (Nasdaq:AVII - News) will present initial data from the second phase of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection at the prestigious International Conference on Antiviral Research (ICAR) annual meeting today. AVI's presentation titled "AVI-4065, An Antisense Approach to Active HCV Infection: Preclinical and Clinical Evaluation" will be presented by Patrick L. Iversen, Ph.D., AVI's senior vice president of research and development. See www.georgetown.edu/research/arc/ISAR for details.
ADVERTISEMENT
The second phase of the trial has been designed to assess the safety, tolerability, pharmacokinetics (PK) and viral and clinical response to treatment with AVI's proprietary NEUGENE® antisense compound, AVI-4065, among HCV patients.
AVI-4065 exhibited favorable safety and tolerability profiles in all patients treated thus far, with no serious drug-related adverse events or tolerability issues observed during treatment or follow-up. Based on the relatively long elimination half-life of AVI-4065 and its mechanism of action, an irreversible binding to the viral genome preventing viral protein synthesis, a slow, steady liver loading with test drug was expected in patients with high levels of viral target in the liver. This correspondingly predicts a slow, steady decrease in viral load over the drug-loading period.
The PK analysis in patients treated thus far was consistent with this prediction; there was a significant decrease in the concentration of drug in the plasma (Cmax) in HCV patients compared with the normal subjects in the initial phase of the trial. This was consistent with an increased elimination of drug found in the urine, most likely bound to the virus in the HCV-infected patients. In addition, there was a significant correlation between viral titer at day one and the extent of reduction in Cmax, further supporting this mechanism of elimination. These observations demonstrate a significant and direct pharmacodynamic response to HCV infection.
Viral responses have been assessed in only a few patients out to the 28th day of the study. During the 14 days of treatment, three of five patients evaluated had an initial decrease in viral load, whereas two of five exhibited little initial change in viral titer. The mean viral titers of all patients tested thus far showed a slight decrease (0.30 log reduction) both during and after treatment, with no rebound effect observed out to 28 days. These are very preliminary results in a small number of patients, and active enrollment and evaluation is ongoing, with formal results expected around the end of the year.
"Based on the PK and mechanism-of-action of our drug, we expected a slow, steady accumulation of drug in the liver with a corresponding decrease in viral load," said Dr. Iversen. "The maximal tissue concentration of drug would be reached in three to five half-lives, or approximately 33 to 55 days. This indicates that an extension of treatment duration is required to reach maximum drug concentration and reduction of viral load in the liver. These preliminary results are consistent with that and very encouraging for ongoing drug development. Extending the treatment period would be expected to further reduce viral load in responding patients and may ultimately decrease viral load in those patients who are not early responders."
"We are pleased to have shown early signs of an anti-HCV response in our first human study," said Denis R. Burger, Ph.D., chief executive officer of AVI. "Because our drug has a significant therapeutic window, we have several options for modifying the therapeutic regimen to enhance the results. Our options include increasing the duration of treatment, increasing the dose, enhancing the delivery, fine-tuning the target, enhancing target affinity, and exploring combinations of antisense agents, or combinations of antisense agents with other drugs. We firmly believe that, after seeing initial trends, we can develop an optimal, viable drug therapy for HCV."
The first phase of this study was completed in March 2006 and evaluated 31 healthy volunteers who received 14 consecutive days of treatment with AVI-4065 at three dosage levels. In the second phase of this clinical trial, patients with HCV are stratified into two cohorts, one composed of patients who have not received previous treatment and the other composed of patients who failed conventional interferon and ribavarin treatment. In addition to efficacy as measured by HCV virological responses to treatment with AVI-4065, the study will continue to assess the safety, tolerability and pharmacokinetics of the compound. Patients will also be monitored for four months following treatment to assess the duration of the virological response to AVI-4065, and sequencing of the viral genome will be performed to assess potential resistance.
HCV is a single-stranded RNA virus. Because HCV and other single-stranded RNA viruses have relatively simple genetic structures, they are attractive targets for AVI's NEUGENE antisense, which is designed to target conserved portions of the viral genetic code that are not likely to mutate over time.
About Hepatitis C Infection
Chronic HCV infection causes an inflammation of the liver that can result in the development of cirrhosis, liver cancer or liver failure. According to the World Health Organization, approximately 170 million people worldwide are chronically infected with HCV. It is the most common chronic blood-borne infection in the developed world and the leading cause of liver transplants in the U.S. The Centers for Disease Control estimates that approximately 3.9 million Americans have been infected with HCV, of whom 2.7 million are chronically infected.
The Hepatitis Foundation International estimates that between 8,000 and 10,000 people die annually in the U.S. from HCV-related cirrhosis or liver cancer. The current treatment for HCV, 24 to 48 weeks of therapy with pegylated interferon alpha and ribavirin, is successful in less than half of the patients infected with genotype 1 HCV, the most common form of the virus in the U.S. Furthermore, this treatment has numerous side effects, some of them severe, which make it difficult for nearly half of initially treated patients to tolerate the recommended dosages and duration of treatment.
About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI has introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. More information about AVI is available on the company's Web site at http://www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
Offenbar waren die Zwischenresultate einer Wirksamkeits-Studie beim Menschen ziemlich lau und konnten auch durch schöne Rhetorik nicht gebessert werden. Man muss offenbar andere Dosierungsschemate probieren (wird als option verkauft ...)
Lest mal den folgenden Artikel:
(meine Vermutung, dass die ein gutes Stück auf der Vogelgrippewelle
mitgepusht haben, hat sich damit wohl bestätigt ...)
http://biz.yahoo.com/bw/060510/20060510005293.html?.v=1
Press Release Source: AVI BioPharma, Inc.
AVI BioPharma Presents Initial Results on Hepatitis C Virus Clinical Trial at the International Conference on Antiviral Research Annual Meeting
Wednesday May 10, 9:00 am ET
PORTLAND, Ore.--(BUSINESS WIRE)--May 10, 2006--AVI BioPharma, Inc. (Nasdaq:AVII - News) will present initial data from the second phase of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection at the prestigious International Conference on Antiviral Research (ICAR) annual meeting today. AVI's presentation titled "AVI-4065, An Antisense Approach to Active HCV Infection: Preclinical and Clinical Evaluation" will be presented by Patrick L. Iversen, Ph.D., AVI's senior vice president of research and development. See www.georgetown.edu/research/arc/ISAR for details.
ADVERTISEMENT
The second phase of the trial has been designed to assess the safety, tolerability, pharmacokinetics (PK) and viral and clinical response to treatment with AVI's proprietary NEUGENE® antisense compound, AVI-4065, among HCV patients.
AVI-4065 exhibited favorable safety and tolerability profiles in all patients treated thus far, with no serious drug-related adverse events or tolerability issues observed during treatment or follow-up. Based on the relatively long elimination half-life of AVI-4065 and its mechanism of action, an irreversible binding to the viral genome preventing viral protein synthesis, a slow, steady liver loading with test drug was expected in patients with high levels of viral target in the liver. This correspondingly predicts a slow, steady decrease in viral load over the drug-loading period.
The PK analysis in patients treated thus far was consistent with this prediction; there was a significant decrease in the concentration of drug in the plasma (Cmax) in HCV patients compared with the normal subjects in the initial phase of the trial. This was consistent with an increased elimination of drug found in the urine, most likely bound to the virus in the HCV-infected patients. In addition, there was a significant correlation between viral titer at day one and the extent of reduction in Cmax, further supporting this mechanism of elimination. These observations demonstrate a significant and direct pharmacodynamic response to HCV infection.
Viral responses have been assessed in only a few patients out to the 28th day of the study. During the 14 days of treatment, three of five patients evaluated had an initial decrease in viral load, whereas two of five exhibited little initial change in viral titer. The mean viral titers of all patients tested thus far showed a slight decrease (0.30 log reduction) both during and after treatment, with no rebound effect observed out to 28 days. These are very preliminary results in a small number of patients, and active enrollment and evaluation is ongoing, with formal results expected around the end of the year.
"Based on the PK and mechanism-of-action of our drug, we expected a slow, steady accumulation of drug in the liver with a corresponding decrease in viral load," said Dr. Iversen. "The maximal tissue concentration of drug would be reached in three to five half-lives, or approximately 33 to 55 days. This indicates that an extension of treatment duration is required to reach maximum drug concentration and reduction of viral load in the liver. These preliminary results are consistent with that and very encouraging for ongoing drug development. Extending the treatment period would be expected to further reduce viral load in responding patients and may ultimately decrease viral load in those patients who are not early responders."
"We are pleased to have shown early signs of an anti-HCV response in our first human study," said Denis R. Burger, Ph.D., chief executive officer of AVI. "Because our drug has a significant therapeutic window, we have several options for modifying the therapeutic regimen to enhance the results. Our options include increasing the duration of treatment, increasing the dose, enhancing the delivery, fine-tuning the target, enhancing target affinity, and exploring combinations of antisense agents, or combinations of antisense agents with other drugs. We firmly believe that, after seeing initial trends, we can develop an optimal, viable drug therapy for HCV."
The first phase of this study was completed in March 2006 and evaluated 31 healthy volunteers who received 14 consecutive days of treatment with AVI-4065 at three dosage levels. In the second phase of this clinical trial, patients with HCV are stratified into two cohorts, one composed of patients who have not received previous treatment and the other composed of patients who failed conventional interferon and ribavarin treatment. In addition to efficacy as measured by HCV virological responses to treatment with AVI-4065, the study will continue to assess the safety, tolerability and pharmacokinetics of the compound. Patients will also be monitored for four months following treatment to assess the duration of the virological response to AVI-4065, and sequencing of the viral genome will be performed to assess potential resistance.
HCV is a single-stranded RNA virus. Because HCV and other single-stranded RNA viruses have relatively simple genetic structures, they are attractive targets for AVI's NEUGENE antisense, which is designed to target conserved portions of the viral genetic code that are not likely to mutate over time.
About Hepatitis C Infection
Chronic HCV infection causes an inflammation of the liver that can result in the development of cirrhosis, liver cancer or liver failure. According to the World Health Organization, approximately 170 million people worldwide are chronically infected with HCV. It is the most common chronic blood-borne infection in the developed world and the leading cause of liver transplants in the U.S. The Centers for Disease Control estimates that approximately 3.9 million Americans have been infected with HCV, of whom 2.7 million are chronically infected.
The Hepatitis Foundation International estimates that between 8,000 and 10,000 people die annually in the U.S. from HCV-related cirrhosis or liver cancer. The current treatment for HCV, 24 to 48 weeks of therapy with pegylated interferon alpha and ribavirin, is successful in less than half of the patients infected with genotype 1 HCV, the most common form of the virus in the U.S. Furthermore, this treatment has numerous side effects, some of them severe, which make it difficult for nearly half of initially treated patients to tolerate the recommended dosages and duration of treatment.
About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI has introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. More information about AVI is available on the company's Web site at http://www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
9:03AM AVI BioPharma: AVI-4065 exhibited favorable safety and tolerability profiles in all patients treated thus far (AVII) 7.26 : Co announces it will present initial data from the second phase of its multicenter study in patients with chronic active hepatitis C virus infection at the International Conference on Antiviral Research meeting today. AVI-4065 exhibited favorable safety and tolerability profiles in all patients treated thus far, with no serious drug-related adverse events or tolerability issues observed during treatment or follow-up. Based on the relatively long elimination half-life of AVI-4065 and its mechanism of action, an irreversible binding to the viral genome preventing viral protein synthesis, a slow, steady liver loading with test drug was expected in patients with high levels of viral target in the liver. This correspondingly predicts a slow, steady decrease in viral load over the drug-loading period.
AVI BioPharma Added to NASDAQ Biotech Index
Tuesday May 23, 9:00 am ET
PORTLAND, Ore.--(BUSINESS WIRE)--May 23, 2006--AVI BioPharma, Inc. (Nasdaq: AVII - News), today announced that the company has been selected for inclusion in the NASDAQ Biotechnology Index (NASDAQ: NBI - News), as of Monday, May 22, 2006
"Being included in the NASDAQ Biotechnology Index is a testament to our steady growth and achievements," said Alan P. Timmins, president and COO of AVI. "We will continue to execute on our goal to develop innovative infectious disease therapeutics and other antisense-based drugs intended to address unmet medical needs."
Launched in 1993, the NASDAQ Biotechnology Index includes companies that are listed on the NASDAQ national market and meet minimum requirements, including market value, average daily share volume and seasoning as a public company, among other criteria. The index is ranked on a semiannual basis in May and November and serves as the basis for the iShares NASDAQ Biotechnology Index Fund. More information about the NASDAQ Biotechnology Index, including eligibility criteria, can be found at http://www.nasdaq.com.
Tuesday May 23, 9:00 am ET
PORTLAND, Ore.--(BUSINESS WIRE)--May 23, 2006--AVI BioPharma, Inc. (Nasdaq: AVII - News), today announced that the company has been selected for inclusion in the NASDAQ Biotechnology Index (NASDAQ: NBI - News), as of Monday, May 22, 2006
"Being included in the NASDAQ Biotechnology Index is a testament to our steady growth and achievements," said Alan P. Timmins, president and COO of AVI. "We will continue to execute on our goal to develop innovative infectious disease therapeutics and other antisense-based drugs intended to address unmet medical needs."
Launched in 1993, the NASDAQ Biotechnology Index includes companies that are listed on the NASDAQ national market and meet minimum requirements, including market value, average daily share volume and seasoning as a public company, among other criteria. The index is ranked on a semiannual basis in May and November and serves as the basis for the iShares NASDAQ Biotechnology Index Fund. More information about the NASDAQ Biotechnology Index, including eligibility criteria, can be found at http://www.nasdaq.com.
AVI BioPharma Receives Notice of Allowance for a Patent Application Covering the Use of NeuGene Antisense Technology for the Development of a New Class of AntibioticsWednesday May 24, 9:00 am ET
PORTLAND, Ore.--(BUSINESS WIRE)--May 24, 2006--AVI BioPharma, Inc. (Nasdaq:AVII - News), today announced that it has received a Notice of Allowance for U.S. Patent No. 7,049,431 titled "Antisense Antibacterial Cell Division Composition and Method." The patent describes the use of NEUGENE ® antisense compounds to target bacterial cell division and cell cycle genes for the development of a new class of antibiotics. This is the central patent covering AVI's antibiotic development program referred to as NeuBiotics.
The patent allowance follows a related publication in the Journal of Antimicrobial Chemotherapy, volume 55/2005, pages 983-988, in which an 11-base NEUGENE compound targeting the acpP gene of E. coli significantly inhibited bacterial growth in both pure culture and in infected mice. These studies showed, for the first time, that an antisense DNA analog can inhibit bacterial growth in animal infections. The relatively short oligomer lengths should offer an improved safety index as they are expected to have no effect on human gene expression.
"This antisense approach to the development of a new class of antibiotics has broad potential to treat infections caused by emerging strains of antibiotic-resistant gram-positive bacteria," said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI. "We believe we can continue to explore the use of NEUGENE antibiotics to include a variety of gene targets, newly emerging infectious disease, and enhance the potency and efficacy in additional animal infection studies."
NeuBiotics are NeuGene antisense compounds containing just 10 to 13 subunits that target prokaryotic (bacteria) genes rather than the typical 18 to 24 subunits used to target higher organisms including man. The shorter antisense polymers are able to gain entry into the more complex bacterial cell wall and inactivate the targeted gene but are too short to inhibit mammalian genes.
PORTLAND, Ore.--(BUSINESS WIRE)--May 24, 2006--AVI BioPharma, Inc. (Nasdaq:AVII - News), today announced that it has received a Notice of Allowance for U.S. Patent No. 7,049,431 titled "Antisense Antibacterial Cell Division Composition and Method." The patent describes the use of NEUGENE ® antisense compounds to target bacterial cell division and cell cycle genes for the development of a new class of antibiotics. This is the central patent covering AVI's antibiotic development program referred to as NeuBiotics.
The patent allowance follows a related publication in the Journal of Antimicrobial Chemotherapy, volume 55/2005, pages 983-988, in which an 11-base NEUGENE compound targeting the acpP gene of E. coli significantly inhibited bacterial growth in both pure culture and in infected mice. These studies showed, for the first time, that an antisense DNA analog can inhibit bacterial growth in animal infections. The relatively short oligomer lengths should offer an improved safety index as they are expected to have no effect on human gene expression.
"This antisense approach to the development of a new class of antibiotics has broad potential to treat infections caused by emerging strains of antibiotic-resistant gram-positive bacteria," said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI. "We believe we can continue to explore the use of NEUGENE antibiotics to include a variety of gene targets, newly emerging infectious disease, and enhance the potency and efficacy in additional animal infection studies."
NeuBiotics are NeuGene antisense compounds containing just 10 to 13 subunits that target prokaryotic (bacteria) genes rather than the typical 18 to 24 subunits used to target higher organisms including man. The shorter antisense polymers are able to gain entry into the more complex bacterial cell wall and inactivate the targeted gene but are too short to inhibit mammalian genes.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 315 | ||
| 160 | ||
| 71 | ||
| 51 | ||
| 40 | ||
| 34 | ||
| 32 | ||
| 31 | ||
| 31 | ||
| 29 |
| Wertpapier | Beiträge | |
|---|---|---|
| 28 | ||
| 28 | ||
| 27 | ||
| 22 | ||
| 22 | ||
| 20 | ||
| 20 | ||
| 18 | ||
| 17 | ||
| 17 |
